Ovulation-stimulation drugs and cancer risks: A long-term follow-up of a British cohort

I. Dos Santos Silva, P. A. Wark, V. A. McCormack, D. Mayer, C. Overton, V. Little, J. Nieto, P. Hardiman, M. Davies, A. B. MacLean

    Research output: Contribution to journalArticle

    73 Citations (Scopus)
    3 Downloads (Pure)

    Abstract

    To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women with ovulatory disorders, 43% of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367 incident cancers. Relative to the general population, the cohort experienced lower mortality from most causes, including from all neoplasms combined, and lower incidence of cervical cancer, but higher incidence of cancers of the breast (relative risk: 1.13; 95% CI 0.97, 1.30) and corpus uteri (2.02; 1.37, 2.87). There were, however, no significant differences in the risk of cancers of the breast, corpus uteri, ovary, or of any other site, between women who had been prescribed ovarian-stimulation drugs and those who had not. Further analyses by type of drug and dose revealed a dose-response gradient in the risk of cancer of the corpus uteri (P for linear trend0.03), with women given 2250 mg of clomiphene having a 2.6-fold (2.62; 0.94, 6.82) increase in risk relative to those who were not treated. These findings do not support strong associations between ovulation-stimulation drugs and cancer risks, but they indicate the need for continued monitoring to establish whether risks are elevated in certain subgroups of users.

    Original languageEnglish
    Pages (from-to)1824-1831
    Number of pages8
    JournalBritish Journal of Cancer
    Volume100
    Issue number11
    Early online date12 May 2009
    DOIs
    Publication statusPublished - 2 Jun 2009

    Fingerprint

    Ovulation
    Ovulation Induction
    Pharmaceutical Preparations
    Neoplasms
    Uterus
    Breast Neoplasms
    Clomiphene
    Uterine Neoplasms
    Incidence
    Uterine Cervical Neoplasms
    Ovary
    Mortality
    Health
    Population

    Keywords

    • Clomiphene
    • Gonadotrophins
    • Infertility
    • Mortality
    • Ovarian stimulation

    ASJC Scopus subject areas

    • Cancer Research
    • Oncology

    Cite this

    Dos Santos Silva, I., Wark, P. A., McCormack, V. A., Mayer, D., Overton, C., Little, V., ... MacLean, A. B. (2009). Ovulation-stimulation drugs and cancer risks: A long-term follow-up of a British cohort. British Journal of Cancer, 100(11), 1824-1831. https://doi.org/10.1038/sj.bjc.6605086

    Ovulation-stimulation drugs and cancer risks : A long-term follow-up of a British cohort. / Dos Santos Silva, I.; Wark, P. A.; McCormack, V. A.; Mayer, D.; Overton, C.; Little, V.; Nieto, J.; Hardiman, P.; Davies, M.; MacLean, A. B.

    In: British Journal of Cancer, Vol. 100, No. 11, 02.06.2009, p. 1824-1831.

    Research output: Contribution to journalArticle

    Dos Santos Silva, I, Wark, PA, McCormack, VA, Mayer, D, Overton, C, Little, V, Nieto, J, Hardiman, P, Davies, M & MacLean, AB 2009, 'Ovulation-stimulation drugs and cancer risks: A long-term follow-up of a British cohort' British Journal of Cancer, vol. 100, no. 11, pp. 1824-1831. https://doi.org/10.1038/sj.bjc.6605086
    Dos Santos Silva, I. ; Wark, P. A. ; McCormack, V. A. ; Mayer, D. ; Overton, C. ; Little, V. ; Nieto, J. ; Hardiman, P. ; Davies, M. ; MacLean, A. B. / Ovulation-stimulation drugs and cancer risks : A long-term follow-up of a British cohort. In: British Journal of Cancer. 2009 ; Vol. 100, No. 11. pp. 1824-1831.
    @article{f10da7ec7fd74e4280a24fc652a9c231,
    title = "Ovulation-stimulation drugs and cancer risks: A long-term follow-up of a British cohort",
    abstract = "To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women with ovulatory disorders, 43{\%} of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367 incident cancers. Relative to the general population, the cohort experienced lower mortality from most causes, including from all neoplasms combined, and lower incidence of cervical cancer, but higher incidence of cancers of the breast (relative risk: 1.13; 95{\%} CI 0.97, 1.30) and corpus uteri (2.02; 1.37, 2.87). There were, however, no significant differences in the risk of cancers of the breast, corpus uteri, ovary, or of any other site, between women who had been prescribed ovarian-stimulation drugs and those who had not. Further analyses by type of drug and dose revealed a dose-response gradient in the risk of cancer of the corpus uteri (P for linear trend0.03), with women given 2250 mg of clomiphene having a 2.6-fold (2.62; 0.94, 6.82) increase in risk relative to those who were not treated. These findings do not support strong associations between ovulation-stimulation drugs and cancer risks, but they indicate the need for continued monitoring to establish whether risks are elevated in certain subgroups of users.",
    keywords = "Clomiphene, Gonadotrophins, Infertility, Mortality, Ovarian stimulation",
    author = "{Dos Santos Silva}, I. and Wark, {P. A.} and McCormack, {V. A.} and D. Mayer and C. Overton and V. Little and J. Nieto and P. Hardiman and M. Davies and MacLean, {A. B.}",
    year = "2009",
    month = "6",
    day = "2",
    doi = "10.1038/sj.bjc.6605086",
    language = "English",
    volume = "100",
    pages = "1824--1831",
    journal = "British Journal of Cancer",
    issn = "0007-0920",
    publisher = "Cancer Research UK",
    number = "11",

    }

    TY - JOUR

    T1 - Ovulation-stimulation drugs and cancer risks

    T2 - A long-term follow-up of a British cohort

    AU - Dos Santos Silva, I.

    AU - Wark, P. A.

    AU - McCormack, V. A.

    AU - Mayer, D.

    AU - Overton, C.

    AU - Little, V.

    AU - Nieto, J.

    AU - Hardiman, P.

    AU - Davies, M.

    AU - MacLean, A. B.

    PY - 2009/6/2

    Y1 - 2009/6/2

    N2 - To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women with ovulatory disorders, 43% of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367 incident cancers. Relative to the general population, the cohort experienced lower mortality from most causes, including from all neoplasms combined, and lower incidence of cervical cancer, but higher incidence of cancers of the breast (relative risk: 1.13; 95% CI 0.97, 1.30) and corpus uteri (2.02; 1.37, 2.87). There were, however, no significant differences in the risk of cancers of the breast, corpus uteri, ovary, or of any other site, between women who had been prescribed ovarian-stimulation drugs and those who had not. Further analyses by type of drug and dose revealed a dose-response gradient in the risk of cancer of the corpus uteri (P for linear trend0.03), with women given 2250 mg of clomiphene having a 2.6-fold (2.62; 0.94, 6.82) increase in risk relative to those who were not treated. These findings do not support strong associations between ovulation-stimulation drugs and cancer risks, but they indicate the need for continued monitoring to establish whether risks are elevated in certain subgroups of users.

    AB - To assess long-term health effects of ovarian-stimulation drugs we followed-up for over 20 years a British cohort of 7355 women with ovulatory disorders, 43% of whom were prescribed ovarian-stimulation drugs, and identified a total of 274 deaths and 367 incident cancers. Relative to the general population, the cohort experienced lower mortality from most causes, including from all neoplasms combined, and lower incidence of cervical cancer, but higher incidence of cancers of the breast (relative risk: 1.13; 95% CI 0.97, 1.30) and corpus uteri (2.02; 1.37, 2.87). There were, however, no significant differences in the risk of cancers of the breast, corpus uteri, ovary, or of any other site, between women who had been prescribed ovarian-stimulation drugs and those who had not. Further analyses by type of drug and dose revealed a dose-response gradient in the risk of cancer of the corpus uteri (P for linear trend0.03), with women given 2250 mg of clomiphene having a 2.6-fold (2.62; 0.94, 6.82) increase in risk relative to those who were not treated. These findings do not support strong associations between ovulation-stimulation drugs and cancer risks, but they indicate the need for continued monitoring to establish whether risks are elevated in certain subgroups of users.

    KW - Clomiphene

    KW - Gonadotrophins

    KW - Infertility

    KW - Mortality

    KW - Ovarian stimulation

    U2 - 10.1038/sj.bjc.6605086

    DO - 10.1038/sj.bjc.6605086

    M3 - Article

    VL - 100

    SP - 1824

    EP - 1831

    JO - British Journal of Cancer

    JF - British Journal of Cancer

    SN - 0007-0920

    IS - 11

    ER -